a Janssen-Cilag , Birkerød , Denmark.
b Department of Clinical Medicine - The Department of General Psyciatry , Aarhus University , Risskov , Denmark.
Psychol Health Med. 2018 Jan;23(1):30-38. doi: 10.1080/13548506.2017.1323108. Epub 2017 May 5.
The objective was to elicit patient preferences for medicine administration method in the management of acute agitation episodes among patients diagnosed with bipolar disorder or schizophrenia. The patients' experiences of acute agitation episodes and their management of episodes were also explored. Data were collected via an anonymous, internet-based survey of residents in Denmark or Sweden with schizophrenia or bipolar disorder (October 2014 to December 2014). Inclusion criteria were having a diagnosis of schizophrenia or bipolar disorder, and being above 18 years of age. The questionnaire included questions about preferences for medication attributes, experiences with pharmacological treatment for agitation and involvement in treatment plans. A total of 237 diagnosed patients (61 with schizophrenia; 176 with bipolar disorder) completed the questionnaire. Agitation episodes were experienced by 90% of the respondents. In total, 83% of the respondents reported having received treatment with tablets. When patients were presented with the attributes of an inhalation method, respondents stated that the fast onset of action, low risk of adverse reactions and least invasive form of drug delivery were positive attributes of treatment with inhalation. Inhalation is a new delivery route for treatment of acute agitation in patients diagnosed with bipolar disorder or schizophrenia. Inhalation is the preferred treatment method for acute agitation among Danish and Swedish patients with bipolar disorder or schizophrenia.
目的是了解双相情感障碍或精神分裂症患者对急性激越发作管理中药物给药方法的偏好。还探讨了患者的急性激越发作经历及其对发作的管理情况。通过丹麦或瑞典的精神分裂症或双相情感障碍患者的匿名在线调查收集数据(2014 年 10 月至 2014 年 12 月)。纳入标准为:被诊断为精神分裂症或双相情感障碍,年龄超过 18 岁。问卷包括对药物属性偏好、激越症药物治疗体验以及参与治疗计划的问题。共有 237 名确诊患者(61 名精神分裂症患者;176 名双相情感障碍患者)完成了问卷。90%的受访者经历过激越发作。总的来说,83%的受访者报告接受过片剂治疗。当患者呈现吸入方法的属性时,受访者表示,起效快、不良反应风险低和最微创的药物输送形式是吸入治疗的积极属性。吸入是治疗双相情感障碍或精神分裂症患者急性激越的新给药途径。吸入是丹麦和瑞典双相情感障碍或精神分裂症患者急性激越的首选治疗方法。